Pivot Pharmaceuticals announced the launch of its R&D and manufacturing facility in Dollard-des-Ormeaux, Quebec, Canada.
Pivot Pharmaceuticals (CSE:PVOT,OTCQB:PVOTF) announced the launch of its R&D and manufacturing facility in Dollard-des-Ormeaux, Quebec, Canada.
As quoted in the press release:
Along with R&D and pilot-scale laboratories, this facility is comprised of 43 000 square feet of production and packaging space designed to optimize the manufacturing processes of Pivot branded value-added CBD and nutraceutical consumer products. The production activities are planned to start in the next three months, pending Health Canada license reception.
Pivot is nearing the completion of its state-of-the-art building and is preparing the submission of its site evidence package to Health Canada, the final step toward securing the Health Canada license. The infrastructure will be dedicated to the development of novel formulations and production of Pivot’s CBD, phytocannabinoid and micronutrient product lines using Pivot’s patented and proprietary drug delivery technologies.